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Anthracycline induced cardiotoxicity in adult cancer patients: a prospective cohort 
study from a specialized oncology treatment centre in Uganda
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Abstract: 
Purpose: To determine the cumulative incidence of  anthracycline induced cardiotoxicity (AIC), its predictors, and associated 
electrocardiographic and echocardiographic manifestations in adult cancer patients at Uganda Cancer Institute (UCI). 
Methods: We enrolled 160 participants between June 2013 and April 2014 and followed them up for a median of  146 days. Data 
on clinical, electrocardiographic and echocardiographic findings was obtained at baseline, and at completion of  chemotherapy. 
The Pearson chi square test was used to identify the predictors associated with cardiotoxicity. 
Results: Of  the 64 patients who were accessible for follow-up electrocardiography (ECG) and echocardiography (ECHO), 
fourteen participants developed cardiotoxicity hence a cumulative incidence rate of  21.9% with 95% CI 13.5%- 33.43%. The 
predictors of  AIC were female gender (p=0.025), LVEF (p=0.014) and LVFS (P=0.019). Anthracycline therapy was associated 
with shortening of  the QRS duration (84.3±7.9 Vs 82.1±11.8 ms, p=0.005), prolongation of  the QTc interval (411.9±30.7 Vs 
447.2±39.4 ms, p=<0.001) and reduction in the LVEF (66.4±7.7 Vs 63.9±8.4%, p=0.026) and LVFS (36.9±6.2 Vs 35.1±6.6%, 
p=0.03). 
Conclusion: The cumulative incidence of  AIC in this study cohort was high. Our findings emphasize the need for early mon-
itoring for AIC.
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Introduction
Anthracyclines have been associated with irreversible car-
diotoxicity and progression to cardiomyopathy and heart 
failure1. These highly potent anti-neoplastic agents are 
used to treat cancers of  the breast, stomach, liver, esoph-
agus, as well as sarcomas, leukemia, lymphomas and my-
eloma. 
Corresponding author:
Solomon Kibudde,
Uganda Cancer Institute, 
Department of  Medical Oncology.
Email: skibudde@yahoo.com
Cardiotoxicity is defined as one or more of  the follow-
ing: cardiomyopathy in terms of  reduction in the left ven-
tricular ejection fraction (LVEF), either global or more 
severe in the septum; symptoms associated with heart 
failure (HF), signs associated with heart failure such as 
S3 gallop, tachycardia or both, reduction in LVEF from 
baseline that is in the range of  less than or equal to 5% 
to less than 55% with accompanying signs or symptoms 
of  heart failure, or a reduction in LVEF in the range of  
equal to or greater than 10% to less than 55%, without 
accompanying signs or symptoms of  HF2.
Anthracycline induced cardiotoxicity is commonly cat-
egorized according to the time of  onset as sub-acute, 
acute or chronic. Sub-acute and acute cardiotoxicity oc-
cur between the time of  chemotherapy initiation to up 
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to 2 weeks after completion of  treatment while chronic 
cardiotoxicity is further classified into early cardiotoxicity 
(onset within one year of  chemotherapy initiation) and 
late (onset after one year of  chemotherapy initiation)3,4. 
Sub acute and acute cardiotoxicity which occurs in up to 
20-30% patients comprises of  transient electrophysio-
logical abnormalities. These include non-specific ST- and 
T-wave flattening, decreased QRS voltage and prolonga-
tion of  QTc interval, sinus tachycardia and supra-ventric-
ular tachycardia. Chronic cardiotoxicity is often associated 
with an irreversible non ischemic dilated cardiomyopathy 
and intractable heart failure5. 
The plausible theory to explain how anthracyclines in-
duce cardiac damage is by free oxygen rich radicals gen-
erated by the anthracycline-iron complexes. This leads to 
progressive left ventricular dilatation, left ventricular wall 
thinning and decreased contractility (irreversible dilated 
cardiomyopathy)6. 
In sub-Saharan Africa (SSA), there is a noted paucity of  
information on burden of  anthracycline induced car-
diotoxicity and related predictors among adult cancer 
patients receiving anthracycline chemotherapy. Most on-
cology centers lack well established guidelines on cardi-
ac monitoring of  patients on cancer chemotherapy, with 
majority of  patients receiving cardiac evaluation only pri-
or to initiation of  chemotherapy.
We therefore conducted this prospective cohort study to 
describe the incidence and predictors of  anthracycline in-
duced cardiotoxicity among adult cancer patients receiv-
ing an anthracycline containing treatment regimen at the 
Uganda Cancer Institute (UCI), a specialized oncology 
treatment centre in Kampala, Uganda.
Methods 
Study design and participants
We conducted a prospective cohort study to describe 
the incidence and predictors of  anthracycline induced 
cardiotoxicity among adult patients receiving anthracy-
cline based chemotherapy at the Uganda Cancer Institute 
(UCI) between the period June 2013 and April 2014. Pa-
tients aged 18 years and older, with histologically con-
firmed diagnosis of  cancer and a doctor’s prescription 
with an anthracycline-containing regimen were consecu-
tively sampled. We excluded patients with history of  prior 
treatment with any anthracycline chemotherapy drugs or 
herceptin/transtuzumab. 
One hundred sixty (160) participants met the inclusion 
criteria and were followed up for up to three months after 
completion of  chemotherapy. Only 64 participants were 
available for the repeat evaluation with ECG and ECHO 
at three months after completion of  chemotherapy as 
shown in Figure 1 below. 
Sample size estimation
Study procedures Treatment, patient evaluation and 
study procedures
All patients were treated according to the standard of  
care at the Uganda Cancer Institute, and the treatment 
regimens are summarized in table 2 below. Pre-tested and 
pre coded questionnaires were used to collect the study 
information in three categories namely; the patients fac-
tors (age, gender, education, presence of  cardiac symp-
toms, family history of  cardiovascular disease, hyper-
tension, BMI, diabetes, performance status and tobacco 
smoking); cancer related factors (cancer type, stage and 
prior chest irradiation); and chemotherapy related factors 
(cumulative dose, type of  anthracycline and combination 
therapy with cyclophosphamide). 
All the study cardiac evaluations with ECG and ECHO 
were done at the cardiac laboratory, Mulago National 
Referral and Teaching Hospital, Uganda; by a certified 
cardiologist. A 12 lead resting ECG was done using the 
Phillips Page Writer Trim III Model. The different read-
ings of  the heart rate (HR), QRS axis, PR interval, QRS 
duration and QTc interval as given by the machine were 
documented and interpretation of  the ECG was per-
formed by the study cardiologist.
The echocardiographic evaluation was done using the 
Phillips HDX10 version employing several modalities in-
cluding the two-dimensional echocardiography, M-mode 
and Doppler echocardiography. All the ECHO dimen-
sions were obtained as per the American Society of  
Echocardiography recommendations9. 
Outcome measures
A repeat ECG and ECHO were done after completion 
of  chemotherapy and all the data was reviewed by the 
cardiologist. The primary end-point was a reduction in 
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the left ventricular ejection fraction (LVEF) of  at least 
10 percent with or without the presence of  symptoms of  
heart failure. The difference in the LVEF was computed 
manually by comparing the pre-treatment LVEF to the 
post-treatment LVEF. Other secondary measurements 
were the change in the left ventricle fractional shorten-
ing (LVFS), the PR interval, QRS duration and the QTc 
interval.
Data management statistical methods
Data was entered using EPI-DATA (version 3.1) software 
and exported to STATA 12.0, for analysis. Continuous 
variables (age, weight, Height, BMI, hemodynamic pa-
rameters, cumulative anthracycline dose, electrocardio-
graphic and echocardiographic evaluation parameters) 
were all presented in the form of  means, standard devia-
tions (SD), medians and inter quartile ranges (IQR). 
Categorical variables (gender, type of  cancer, type of  
anthracycline, outcome variables) were presented in fre-
quencies and percentages. The Pearson chi square test 
was used to identify the predictors associated with cardio-
toxicity. Variables with a p value ≤0.05 were considered as 
statistically significant.  
Ethical considerations
Ethical approval was obtained from the Department of  
Medicine, Makerere University College of  Health Scienc-
es, the School of  Medicine Research and Ethics Commit-
tee (SOMREC) and the Ethics and Research Committee 
of  Uganda Cancer Institute. In addition, signed written 
informed consent was obtained from every participant 
using board approved consent forms in either English or 
a translated local language. 
Results
Socio demographic and clinical characteristics of  
study participants
Of  the 160 study participants enrolled, majority were fe-
males (124, 77.50%) giving a female to male ratio of  3.4: 
1. The mean age of  the study participants was 42.29 years 
(SD -13.73 years). Cancer of  the breast was the most pre-
dominant diagnosis in this study cohort (n=110, 68.75%) 
followed by Non-Hodgkin’s Lymphoma (n=21; 13.13%). 
All the 160 patients had advanced stages of  disease (stage 
III/IV) and the majority had a good performance status 
between level 0 and 1 (n= 147, 92.5%). The performance 
status was assessed using the scale developed by the East-
ern Cooperative Oncology Group (ECOG). Nine (9) 
patients were excluded because they did not receive any 
chemotherapy due to disease progression and early loss 
to follow up. Sixteen patients (10%) died during the pe-
riod of  follow up, while 80 patients (50%) patients were 
lost to follow up before completion of  chemotherapy, 
and only 64 patients returned for follow up cardiac eval-
uation within three months of  chemotherapy completion 
(Figure 1 summarizes the patient flow during the study). 
Of  the 64 patients who had follow up cardiac evaluation 
within three months after completion of  chemotherapy, 
48 (80%) were female. Their mean age was 44.3 + 13.1 
years and the majority (43, 67.2%) had breast cancer. The 
mean values for the full hemogram, liver and renal func-
tion tests for all the patients in this study cohort were all 
within normal limits. The socio-demographic and clinical 
profile of  the study participants is shown in Table 1.
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 Table 1: Socio- demographic and clinical characteristics of the study participants 
 
Characteristic Cases (N=160) 
Age, median (IQR) 45.3(35.3-55.8) 
Gender   
Female, n (%) 124(77.5%) 
BMI, median (IQR) 24.6(21.2-28.1) 
HIV sero positive, n (%) 27 (16.9%)        
ECOG, n (%)   
0/1 147 (92.5%) 
2/3 12 (7.5%) 
Stage, n (%)   
I/II 0 (0%) 
III 86 (64.2%)        
IV 48 (35.8%)       
Hb, median (IQR) 12.3(10.6-14.1) 
ALT, median (IQR) 16.7(12.0-23.1) 
AST, median (IQR) 23.7(20.2-33.1) 
Cr, median (IQR) 75.0(61.3-83.8) 
LDH, median (IQR) 270(197-330) 
 
Note: BMI – Body mass Index, Hb – Hemoglobin, WCC – White Cell Count, Plt – Platelet,  
ALT – Alanine Transaminase, AST – Aspartate Transaminase, T-Prot – Total Protein, Cr – Creatinine,  
LDH – Lactate Dehydrogenase. 
Patients screened (n=169)
Lost to follow-up 
(n=36)
Excluded:
Age < 18 (n=2)
ECOG >3 (n= 6)
Herceptin (n=1)
Patients available for follow up 
ECG/ECHO at completion 
(n=64)
Patients enrolled and had 
baseline ECG/ECHO (n=160)
Ca Breast (n=43)
NHL (n=10)
HD (n=4)
AML (n=2)
ALL (n=1)
AML (n=0)
HCC (n=3)
Sarcoma (n=1)
Others (n=0)
Dead (n=16)
Alive (n=107)
Ca Breast (n=110)
NHL (n=21)
HD (n=9)
AML (n=4)
ALL (n=1)
HCC (n=6)
Sarcoma (n=6)
Others (n=3)
Figure 1: Study flow diagram showing the cohort at different stages
Note: NHL – Non-Hodgkin’s Lymphoma, HD – Hodgkin’s Disease, AML – Acute Myeloid Leukemia, ALL – Acute Lymphoblastic Leukemia, 
HCC – Hepatocellular Carcinoma,  ECG – Electrocardiogram, ECHO – Echocardiogram, ECOG – Eastern Cooperative Oncology Group 
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Cumulative incidence of  anthracycline induced car-
diotoxicity
The median duration of  follow up of  the study partici-
pants was 146 days with a range of  23 days to 260 days. 
Fourteen (14) out of  64 patients developed anthracycline 
induced cardiotoxicity within three months of  complet-
ing anthracycline based chemotherapy; hence the cumu-
lative incidence rate of  21.9% with 95% confidence inter-
vals (13.50% - 33.43%). Only one person developed overt 
signs and symptoms of  heart failure.
Predictors of  anthracycline induced cardiotoxicity;
Pearson chi square test was used to identify the statis-
tically significant variables associated with anthracycline 
induced cardiotoxicity; only female gender (p=0.025), 
pre-treatment LVEF (p=0.014) and  pre-treatment LVFS 
(0.019) were noted 
Clinical, electrocardiographic and electrocardiographic 
characteristics associated with anthracycline induced car-
diotoxicity were female gender (p=0.025), pre-treatment 
LVEF ≤ 55% (p= 0.001) and pre-treatment LVFS ≤30% 
(p= 0.04) (illustrated in table 3). 
Table 2: Diagnosis and schedule of chemotherapy among the patients evaluated for 
anthracycline-induced cardiotoxicity 
Diagnosis  Patients. (n=160) Regimen Schedule Cycles received 
Breast cancer 110 (68.8%)         CA†F 3 weekly 6 (4–6) 
NHL 21(13.1%)         CHOP 3 weekly 3 (2-6) 
HD 09 (5.6%)         A†BVD 2 weekly 3 (2-6) 
AML 04 (2.5%) Dauno/AraC Daily 3 (3-5) 
ALL 01 (0.6%) DVPA‡ Daily 3 (3-3) 
HCC 06 (3.7%)         Doxorubicin Weekly 6 (3-6) 
Sarcomas 06 (3.7%)         A†D 3 weekly 6 (0-6) 
 
Note: A† – Adriamycin/(Doxorubicin/Hydroxydaunorubicin[H]), A‡ - L –Asparaginase, AraC – Cytarabine,  
B –Bleomycin, C – Cyclophosphamide, D – Dacarbazine, F - %-Fluorouracil, O – Oncovin/(Vincristine[V]),  
P – Prednisone, H –/(Adriamycin/Doxorubicin)   
contained in chemotherapy prescriptions of  majority of  
patients (n=155, 96.88%). The most prescribed treatment 
dose of  Doxorubicin was 100mg/m2 especially in the 
chemotherapy regimen for breast cancer. 
Chemotherapy regimens used during the study
The cancer chemotherapy regimens used for patients 
enrolled in this cohort are shown in Table 2. Doxorubi-
cin alone or in combination with cyclophosphamide was 
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However, we observed these significant differences 
in ECG and ECHO parameters at 3 months after an-
thracycline treatment: shortening of  the QRS duration 
(84.3±7.9ms Vs 82.1±11.8ms, p=0.005), prolongation 
of  the QTc interval (411.9±30.7ms Vs 447.2±39.4ms, 
p=<0.001) and reduction in the LVEF (66.4±7.7% 
Vs 63.9±8.4%, p=0.026) and LVFS (36.9±6.2% Vs 
35.1±6.6%, p=0.03) (illustrated in table 4 below).
Table 3: Clinical, electrocardiographic and electrocardiographic characteristics  
associated with anthracycline induced cardiotoxicity 
 
Variable   Anthracycline induced 
cardiotoxicity 
Chi 
square 
(X2) 
p-value 
Cardiotoxicity 
(N=14) 
No Cardiotoxicity 
(N=50) 
Gender Male 0 (0.00%) 14 (28.00%) 5.02 0.025 
Female 14 (100.00%) 36 (74.00%)     
Age (years) 18-49 10(71.4) 33(66.0) 0.15 0.702 
50-73 4(28.6) 17(34.0)     
Education‡ Post-primary 5(35.7) 24(51.1) 1.02 0.97 
Yes 2 (14.29%) 9 (18.00%)     
Tobacco smoking No 14 (100.00%) 48 (96.00%) 0.58 0.447 
Yes 0 2 (4.00%)     
HIV No 13 (92.86%) 38 (76.00%) 1.92 0.166 
Yes 1 (7.14%) 12 (24.00%)     
Diabetes No 14 (100.00%) 48 (96.00%) 0.58 0.447 
Yes 0 2 (4.00%)     
ECOG 0 5 (35.71%) 15 (30.00%) 0.48 0.787 
1 8 (57.14%) 33 (66.00%)     
2 1 (7.14) 2 (4.00%)     
LVEF <55  6 (60.0%) 4 (40.00%) 18.7 <0.001 
55-65  8 (33.3%) 16 (66.7%)     
>65  0 (0.00%) 30 (100%)     
LVFS <30 6 (46.1%) 7 (53.9%) 6.43 0.040 
30-45 8 (14.29%) 38 (82.6%)     
>45 0 (0.00%) 5 (100.0%)     
E:A 0.6-1  8 (22.9%) 27 (77.1%) 0.02 0.892 
>1 6 (21.4%) 22 (78.6%)     
Cumulative dose ‡ <550mg/m2 9(21.4) 33(78.6) 0.28 0.594 
>550mg/m2 5(27.8) 13(72.2)     
Statistically significant P<0.05 
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Table 4: Difference in the electrocardiographic and echocardiographic parameters 
withinthree months after completion of chemotherapy 
  Baseline End  of Chemotherapy P- value 
ECG parameters 
PR interval (mSec) 
QRSduration (mSec)  
QTc interval (mSec) 
  
154.2 ± 27 
84.27 ± 7.9 
411.9 ± 30.7 
  
154.2 ± 24.1 
82.1 ± 11.8 
447.2 ± 39.4 
  
0.979 
0.005 
<0.001 
ECHO parameters 
LVEF (%) 
LVFS (%) 
E:A Ratio 
  
66.4 ± 7.7 
36.9 ± 6.2 
1.07 ± 0.3 
  
63.9 ± 8.4 
35.1± 6.6 
1.03 ± 0.3 
  
0.026 
0.030 
0.278 
Note: † - parameters are expressed as means ± standard deviation. 
  
With regard to the measured LVEF, we observed a great-
er reduction in the LVEF among the age group of  18 
-45 years as compared to other age groups (illustrated in 
figure 2). 
This observation could be explained by the relatively 
higher number of  patients in the age group 18-45 years 
who had a follow up measure of  the LVEF after com-
pletion of  chemotherapy. The change in the LVEF was 
higher among patients with hematological malignancies 
compared to those with solid tumors (illustrated in figure 
3).
Figure 2 showing the change in ejection fraction by the different age groups.
Table 4: Difference in the electrocardiographic and echocardiographic parameters 
withinthree months after completion of chemotherapy 
  Baseline End  of Chemotherapy P- value 
ECG parameters 
PR interval (mSec) 
QRSduration (mSec)  
QTc interval (mSec) 
  
154.2 ± 27 
84.27 ± 7.9 
411.9 ± 30.7 
  
154.2 ± 24.1 
82.1 ± 11.8 
447.2 ± 39.4 
  
0.979 
0.005 
<0.001 
ECHO parameters 
LVEF (%) 
LVFS (%) 
E:A Ratio 
  
66.4 ± 7.7 
36.9 ± 6.2 
1.07 ± 0.3 
  
63.9 ± 8.4 
35.1± 6.6 
1.03 ± 0.3 
  
0.026 
0.030 
0.278 
Note: † - parameters are expressed as means ± standard deviation. 
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Discussion
To our knowledge, this is the first prospective cohort 
study to examine the incidence and predictors of  anth-
racycline induced cardiotoxicity in adult cancer patients 
in Uganda. Our findings demonstrate a high incidence of  
anthracycline-induced cardiotoxicity in this cohort with 
one among every five patients (21.9%) developing sig-
nificant reduction in the left ventricular ejection fraction. 
Furthermore, the predictors for anthracycline induced 
cardiotoxicity were female gender, and a reduction in the 
left ventricular ejection fraction and/or the left ventricle 
fraction shortening.  The significant ECG changes were 
shortening of  the QRS duration, and prolongation of  the 
QTc interval.
Anthracycline-induced cardiotoxicity is a dose-dependent 
toxicity with a recommended threshold of  550mg/m2 for 
Adriamycin (doxorubicin); in our cohort, nearly one third 
of  patients (18 out of  the 64 participants) exceeded the 
ceiling dose of  anthracycline chemotherapy.  Secondly, 
the presentation is sub-clinical in majority of  patients; 
and hence the importance of  clinical vigilance among 
patients receiving anthracycline-based chemotherapy. Re-
duction in left ventricle ejection fraction was consistent 
with increased risk for cardiac dysfunction as previously 
reported. ECG findings associated with anthracycline-in-
duced cardiotoxicity remain non-specific but could be 
predictive. The shortening of  the QRS duration implies a 
reduction of  the myocardium depolarization time hence 
increasing the myocardium repolarization time. 
Our findings are in-line with similar studies including 
three from Africa with reported incidence of  anthracy-
cline induced cardiotoxicity ranging from 0% to 47%10-14. 
In Africa, two studies done among adult cancer patients 
in Cote d ívore and Morocco show a high incidence of  
anthracycline-induced cardiotoxicity. Elalouani C et al 
who conducted a prospective cohort study in Morocco 
investigating the frequency of  anthracycline induced car-
diotoxicity noted that 56% of  the 70 patients developed 
a decrease in cardiac function and 4% of  cases developed 
severe cardiotoxicity15. In another prospective cohort 
study by Pio M et al conducted at Abidjan institute of  
cardiology, Cote d ívore over 10 months,  45 adult pa-
tients were followed up and 4 (8.8%) developed signifi-
cant cardiotoxicity16.
In another study by Shiroya –Wandabwa M et al done in 
110 children being treated with doxorubicin with a cumu-
lative dose > 200mg/m2  at Kenyatta National Hospital, 
Nairobi, Kenya, a comparable point prevalence of  anth-
racycline induced cardiotoxicity of  29%, 95% CI 21.2-
37.9 was documented17. 
Predictors of  anthracycline induced cardiotoxicity
Described predictors of  anthracycline induced cardiotox-
icity include: the type of  anthracycline, cumulative dose, 
and presence of  additional risk factors for developing 
Figure 3: Box plot showing change in left ventricle ejection fraction according to 
the different cancers.
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heart damage such as chest irradiation, tumor type, com-
bination chemotherapy with cyclophosphamide, female 
gender, extremes of  ages and malnutrition5,18.  In our 
study, we identified female gender, LVEF and LVFS as 
strongly predictive of  anthracycline induced cardiotoxic-
ity. Of  note, the majority of  our patients were female, 
and all patients received combination chemotherapy with 
mostly cyclophosphamide. 
Clinical, electrocardiographic and echocardiograph-
ic features of  anthracycline induced cardiotoxicity
In this study, the following variables were noted to be 
associated with anthracycline induced cardiotoxicity: fe-
male gender, LVEF ≤ 55% and LVFS ≤30%. The signif-
icant ECG and ECHO changes that were documented 
3 months after completion of  chemotherapy included: 
shortening of  the QRS duration, prolongation of  the 
QTc interval, and reduction in the LVEF (illustrated in 
table 3). These observations are in agreement with find-
ings from previous studies and in literature14,19-21. 
The co-morbid conditions and clinical features that we 
evaluated included presence of   hypertension, diabetes 
mellitus, history of  angina or heart failure or sudden 
death, family history of  any cardiovascular disease, car-
diac symptoms (dyspnoea on exertion, chest discomfort, 
ankle swelling, orthopnoea and easy fatigability) and they 
were all not associated with cardiotoxicity. This probably 
could have been due to limited number of  patients eval-
uated in this study. 
Study limitations
We encountered several limitations during the conduct 
of  this research. First, there was a high rate of  loss to 
follow up attributed to fluctuation in the availability of  
chemotherapy at UCI; compounded by low education 
level, family’s myths about cancer treatment and financial 
constraints especially transport fares. Secondly, we recog-
nize that the study follow-up period was short thus lim-
iting the events of  cardiotoxicity that could be observed. 
Thirdly, during this study, we were unable to perform se-
rial echocardiography prior every cycle of  chemotherapy 
so as to determine the exact time when the cardiotoxicity 
sets in; and lastly, we were unable to do Tissue Doppler 
Imaging (TDI) to assess diastolic function; this makes it 
difficult to differentiate true versus pseudo diastolic heart 
dysfunction just based on the E: A ratios we observed.
 
Conclusion 
Our findings demonstrate a high incidence of  anthracy-
cline induced cardiotoxicity within three months of  com-
pletion of  chemotherapy in this study cohort. Therefore, 
we strongly recommend that all cancer patients receiving 
anthracycline based chemotherapy should have cardiac 
evaluation with at least a left ventricle ejection fraction 
(LVEF) before, during and after completion of  chemo-
therapy. 
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